An estimated 1.9 million new cancer cases are reported per year, according to the National Cancer Institute (NCI). Yet this growing group has been all but bypassed by the COVID-19 research wave, from vaccine to therapeutic trials. Given the success thus far in terms of mitigating transmission and disease progression, it’s not known what kinds of impacts these vaccines have on various cancers. This extends worldwide to the approximately 19 million people that will be diagnosed with cancer in 2021 alone. But the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research suggest a change is in order.
The CDC guidelines point out that cancer is a high-risk medical condition that subjects patients to severe illness from the coronavirus. Thus the threat of COVID-19, at least in some hot spots around the world. So, ASCO along with the European Society for Medical Oncology (ESMO) and other oncology professional organizations recommend vaccination unless specifically contraindicated.
In ASCO’s letter, the organization shares that in the case of many vaccines using live viruses, the risk for viral transmission thus precludes participation. But according to the medica...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).